Claims
- 1. A composition comprising at least one component selected from the group consisting of:
(a) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis; (b) delipidated and deglycolipidated M. vaccae cells that have been treated by acid hydrolysis; (c) delipidated and deglycolipidated M. vaccae cells that have been treated with periodic acid; (d) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (e) delipidated and deglycolipidated M. vaccae cells that have been treated by alkaline hydrolysis and treated with periodic acid; (f) delipidated and deglycolipidated M. vaccae cells that have been treated with Proteinase K; and (g) delipidated and deglycolipidated M. vaccae cells that have been treated by hydrofluoric acid hydrolysis.
- 2. A composition comprising a component prepared by:
(a) inactivating Mycobacterium vaccae cells; (b) freeze-drying the inactivated cells to provide a freeze dried material; (c) contacting the freeze dried material with a chloroform-methanol mixture in an amount sufficient to extract lipids to provide a delipidated material; (d) refluxing the delipidated material with an ethanol-water mixture in an amount sufficient to remove glycolipids to provide a delipidated and deglycolipidated material; and (e) contacting the delipidated and deglycolipidated material with sulfuric acid in an amount sufficient to cleave acid-labile linkages to provide the component.
- 3. The composition of claim 2, wherein the component contains galactose in an amount less than 9.7% of total carbohydrate.
- 4. The composition of claim 2, wherein the component contains glucosamine in an amount greater than 3.7% of total carbohydrate.
- 5. The composition of claim 2, wherein the component is depleted of arabinogalactan compared to untreated delipidated and deglycolipidated M. vaccae cells.
- 6. The composition of claim 2, wherein the component contains galactosamine in an amount less than 26.6% of total carbohydrate.
- 7. The composition of claim 2, wherein the component contains glucose in an amount greater than 56.9% of total carbohydrate.
- 8. The composition of claim 2, wherein the component contains mannose in an amount greater than 3.2% of total carbohydrate.
- 9. The composition of any one of claims 1 and 2, wherein the composition is effective at modulating the amount of an interleukin molecule involved in an antigen-specific Th2-mediated immune response in a patient.
- 10. A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims 1 and 2, the disorder being selected from the group consisting of: disorders of the respiratory system and allergic disorders.
- 11. The method of claim 10, wherein the disorder is selected from the group consisting of: mycobacterial infections, asthma, sarcoidosis, allergic rhinitis, and atopic dermatitis and lung cancers.
- 12. A method for the reduction of eosinophilia in a patient, comprising administering to the patient a composition according to any one of claims 1 and 2.
- 13. A method for enhancing IL-10 production, comprising administering a composition according to any one of claims 1 and 2
- 14. A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims 1 and 2, wherein the disorder is selected from the group consisting of: atherosclerosis; cancer; hypercholesterolemia; bacterial infections; and insulin-dependent diabetes mellitus.
- 15. A method for activating γδ T cells, γδ T cells or NK cells in a patient, comprising administering a composition of any one of claims 1 and 2.
- 16. A method for repairing epithelium in a patient, comprising administering a composition of any one of claims 1 and 2.
- 17. A method for modulating a disorder characterized by an antigen specific Th2-mediated immune response in a patient, comprising administering a composition of any one of claims 1 and 2 to the patient.
- 18. The method of claim 17, wherein the disorder is selected from the group consisting of:
(a) an hypersensitivity immune reaction; (b) a pathogenic immune response caused by excessive Th2 activation; and (c) a disorder caused by the suppression of a IFN-gamma-mediated immune function.
- 19. The method of claim 18, wherein the hypersensitivity reaction is associated with a disorder selected from the group consisting of: atopic dermatitis; asthma; and allergic rhinitis.
- 20. A method for preventing or reducing the severity of an immune response to a specific antigen in a patient, comprising administering to the patient the specific antigen and a composition of any one of claims 1 and 2.
- 21. A composition comprising at least one component selected from the group consisting of:
(a) delipidated and deglycolipidated mycobacterial cells that have been treated by alkaline hydrolysis; (b) delipidated and deglycolipidated mycobacterial cells that have been treated by acid hydrolysis; (c) delipidated and deglycolipidated mycobacterial cells that have been treated with periodic acid; (d) delipidated and deglycolipidated mycobacterial cells that have been treated by alkaline hydrolysis and by acid hydrolysis; (e) delipidated and deglycolipidated mycobacterial cells that have been treated by alkaline hydrolysis and treated with periodic acid; (f) delipidated and deglycolipidated mycobacterial cells that have been treated with Proteinase K; and (g) delipidated and deglycolipidated mycobacterial cells that have been treated by hydrofluoric acid hydrolysis.
- 22. The composition of claim 21, wherein the mycobacterial cells are selected from the group consisting of: Mycobacterium tuberculosis and Mycobacterium smegmatis.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of copending U.S. application Ser. No. 09/710,425, filed Nov. 8, 2000, which is a continuation-in-part of U.S. application Ser. No. 09/449,013, filed Nov. 24, 1999, now U.S. Pat. No. 6,350,457, which claims priority to U.S. Provisional Application No. 60/137,112, filed Jun. 2, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60137112 |
Jun 1999 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09710425 |
Nov 2000 |
US |
Child |
10825709 |
Apr 2004 |
US |
Parent |
09449013 |
Nov 1999 |
US |
Child |
09710425 |
Nov 2000 |
US |